Stockreport

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease [Yahoo! Finance]

Opus Genetics, Inc.  (IRD) 
PDF Initial data expected in Q1 2026 RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Opus Genetics , (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a c [Read more]